Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
Retrieved on:
Mercredi, février 14, 2024
Viral, Internet, Call, MAMC, Blood, Interest, Exosome, Marketing, Maulana Azad Medical College, Metastasis, Organ transplantation, Ethics, Interim, Intensive care medicine, COVID-19, Consolidated, DCGI, Virus, Patient, Clinical trial, Infection, Plasma, Insurance, Research, Travel, Cancer, Pharmaceutical industry
SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2023 and provided an update on recent developments.
Key Points:
- ET
SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2023 and provided an update on recent developments. - "While our research and development team has started to quantify our internal data, the results, to date, are inconclusive.
- Financial Results for the Third Quarter Ended December 31, 2023
As of December 31, 2023, Aethlon Medical had a cash balance of approximately $8.0 million. - ET to review its financial results for its fiscal third quarter ended December 31, 2023 and recent corporate developments.